STO · SIMRIS-B.ST
Simris Alg AB (publ)
SEK 0.13+SEK 0.00 (+2.88%)
Simris Alg AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
Loading market information…
STO · MODTX.ST · SEK
Stock price, earnings
Quote as of Oct 30, 2026, 08:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Modus Therapeutics Holding AB’s quoted price sits in the lower half of its reported 52-week range, 70.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Modus Therapeutics Holding AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 0.13+SEK 0.00 (+2.88%)
Simris Alg AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
SEK 0.06+SEK 0.00 (0.0%)
Episurf Medical AB’s quoted price sits in the lower half of its reported 52-week range, 79.55% below the high.
SEK 0.20+SEK 0.00 (0.0%)
Aino Health AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
SEK 1.47SEK 0.00 (0.0%)
Guard Therapeutics International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.56% below the high.
SEK 1.00-SEK 0.10 (-8.93%)
Qlife Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 73.68% below the high.
SEK 0.21SEK 0.00 (0.0%)
Stayble Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
SEK 0.42-SEK 0.06 (-12.13%)
2cureX AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.16% below the high.
